Which medication is FDA-approved for the treatment of Bulimia Nervosa?

Fluoxetine is the only antidepressant FDA-approved for Bulimia Nervosa, typically at a higher dose than for depression (e.g., 60 mg/day).

Are there any FDA-approved medications specifically for Anorexia Nervosa?

No, there are currently no FDA-approved medications specifically for Anorexia Nervosa. Treatment primarily focuses on nutritional rehabilitation and psychotherapy.

Why is bupropion contraindicated in patients with Anorexia Nervosa or Bulimia Nervosa?

Bupropion is contraindicated due to an increased risk of seizures in patients with current or prior diagnoses of Anorexia Nervosa or Bulimia Nervosa, likely related to electrolyte disturbances and metabolic derangements.

What is the role of lisdexamfetamine in the pharmacological management of eating disorders?

Lisdexamfetamine is FDA-approved for the treatment of moderate to severe Binge Eating Disorder (BED) in adults, helping to reduce binge eating days.

When might antipsychotics like olanzapine be considered in Anorexia Nervosa?

Olanzapine may be used off-label in Anorexia Nervosa, particularly in patients who have failed other interventions, to help with weight gain, reduce anxiety around food, and address distorted body image or obsessive thoughts, typically after initial weight restoration.

What are critical monitoring parameters for patients with eating disorders receiving psychotropic medications?

Key monitoring parameters include electrolytes (potassium, magnesium, phosphate), ECG for QTc prolongation, vital signs (heart rate, blood pressure), weight, renal and hepatic function, and mental status for psychiatric symptoms and medication side effects.

How do comorbidities such as depression or anxiety impact the pharmacological approach to eating disorders?

Comorbid psychiatric conditions are common and often require concurrent treatment. Addressing comorbidities can improve overall outcomes, but medication selection must consider potential interactions with the eating disorder and its physiological consequences (e.g., SSRIs for depression/anxiety in BN, but careful monitoring for cardiac effects).

What is Avoidant/Restrictive Food Intake Disorder (ARFID) and its pharmacological treatment?

ARFID is characterized by restricted food intake not due to body image concerns. There are no FDA-approved medications for ARFID; treatment is primarily behavioral therapy and nutritional support. Pharmacotherapy may target co-occurring anxiety, depression, or GI symptoms.

Eating Disorders Pharmaceutical Interventions: Essential for the BCPP Board Certified Psychiatric Pharmacist Exam

Introduction: Navigating Eating Disorder Pharmaceutical Interventions for BCPP Success

Eating disorders represent a complex group of psychiatric conditions characterized by severe disturbances in eating behaviors, thoughts, and emotions. These disorders, including Anorexia Nervosa (AN), Bulimia Nervosa (BN), Binge Eating Disorder (BED), and Avoidant/Restrictive Food Intake Disorder (ARFID), carry significant morbidity and mortality, making them a critical area of focus for psychiatric pharmacists. For those preparing for the Complete BCPP Board Certified Psychiatric Pharmacist Guide, understanding the nuanced role of pharmaceutical interventions is paramount. While psychotherapy and nutritional rehabilitation form the cornerstone of treatment, pharmacotherapy often plays a vital role in managing core symptoms, reducing relapse risk, and treating common psychiatric comorbidities. As of April 2026, the landscape of eating disorder treatment continues to evolve, emphasizing evidence-based approaches and patient-centered care. A deep dive into this topic ensures you are well-prepared for the BCPP Board Certified Psychiatric Pharmacist exam, demonstrating expertise in a challenging yet crucial area of mental health.

Key Concepts: Detailed Explanations of Pharmacological Strategies

Pharmacological interventions for eating disorders are often adjunctive to psychotherapy and nutritional support, with specific agents indicated for different diagnoses and symptom profiles. The BCPP exam will test your ability to differentiate these approaches.

Anorexia Nervosa (AN)

Anorexia Nervosa is characterized by an intense fear of gaining weight, a distorted body image, and severely restricted food intake leading to dangerously low body weight. It has the highest mortality rate of any psychiatric illness. The primary treatment goals are weight restoration and normalization of eating patterns.

First-line Treatment: Family-Based Treatment (FBT) for adolescents and various psychotherapies (e.g., CBT-E, specialist supportive clinical management) for adults, alongside medical stabilization and nutritional rehabilitation.
Pharmacological Role: There are no FDA-approved medications for Anorexia Nervosa. Pharmacotherapy is generally not effective for weight gain or core AN symptoms directly.
Off-label Use:
- Olanzapine: Often used off-label, especially in severely underweight patients or those with significant anxiety, rumination, or distorted body image. Evidence suggests it may promote modest weight gain and reduce obsessive thoughts about food and body shape. Dosing typically starts low (e.g., 2.5-5 mg/day) and can be titrated. However, its use is debated and requires careful monitoring for metabolic side effects.
- SSRIs (e.g., Fluoxetine): Generally ineffective for weight restoration or core AN symptoms while the patient is underweight. They may be considered after weight restoration has been achieved to prevent relapse or treat comorbid depression/anxiety. Starting an SSRI in a severely underweight patient can be risky due to potential cardiac effects and is generally not recommended.
Important Consideration: Medications like bupropion are absolutely contraindicated due to the increased seizure risk in underweight patients and those with electrolyte imbalances.

Bulimia Nervosa (BN)

Bulimia Nervosa involves recurrent episodes of binge eating followed by compensatory behaviors (e.g., self-induced vomiting, laxative misuse, excessive exercise). Patients are typically at a normal weight or overweight.

First-line Treatment: Cognitive Behavioral Therapy, specifically CBT-E (enhanced CBT), is the gold standard.
Pharmacological Role:
- Fluoxetine: This is the only FDA-approved medication for Bulimia Nervosa. It is effective in reducing the frequency of binge eating and purging episodes, as well as improving mood. The FDA-approved dose is typically higher than for depression, often 60 mg/day, administered once daily. Patients usually experience improvement within a few weeks.
- Other SSRIs: While not FDA-approved, other SSRIs (e.g., sertraline, citalopopram, escitalopram) may be used off-label to treat comorbid depression or anxiety, and may have some benefit in reducing binge/purge behaviors, but fluoxetine has the strongest evidence base.
- Tricyclic Antidepressants (TCAs): Historically used, but their side effect profile (anticholinergic, cardiac) makes them less favorable than SSRIs.
Contraindication: Bupropion is strictly contraindicated in BN due to the significantly increased risk of seizures in patients with a history of purging.

Binge Eating Disorder (BED)

Binge Eating Disorder is characterized by recurrent episodes of eating unusually large amounts of food in a short period, accompanied by a sense of loss of control, and significant distress, without regular compensatory behaviors.

First-line Treatment: Psychotherapy, particularly CBT, Interpersonal Psychotherapy (IPT), and Dialectical Behavior Therapy (DBT).
Pharmacological Role:
- Lisdexamfetamine (Vyvanse): This is the only FDA-approved medication for moderate to severe Binge Eating Disorder in adults. It is a stimulant that helps reduce binge eating days. Dosing starts low (e.g., 30 mg/day) and is titrated up to a maximum of 70 mg/day. Careful monitoring for stimulant side effects (e.g., insomnia, dry mouth, increased heart rate, blood pressure) and potential for abuse is essential.
- SSRIs (e.g., Sertraline, Citalopram, Fluoxetine): Often used off-label, especially if there are comorbid depression or anxiety symptoms. They can help reduce binge frequency and associated distress.
- Topiramate: Used off-label for BED, it can lead to weight loss and reduced binge frequency. However, its use is limited by a significant side effect profile, including cognitive impairment ("fogginess"), paresthesias, and kidney stones. Requires careful titration.
- Zonisamide: Another anticonvulsant used off-label, similar to topiramate, with similar side effects and efficacy concerns.

Avoidant/Restrictive Food Intake Disorder (ARFID)

ARFID involves restricted food intake leading to nutritional deficiency, weight loss, or functional impairment, but without body image concerns. It's often seen in children and adolescents.

Pharmacological Role: There are no specific medications for ARFID. Treatment is primarily behavioral and nutritional. Pharmacotherapy may be considered to address co-occurring conditions like anxiety, depression, or gastrointestinal issues.

General Pharmacological Principles and Considerations

Comorbidities: Eating disorders frequently co-occur with other psychiatric conditions such as depression, anxiety disorders (especially OCD and social anxiety), substance use disorders, and personality disorders. Treating these comorbidities can significantly improve overall outcomes for the eating disorder. Pharmacists must be adept at selecting agents that are safe and effective in the context of the eating disorder.
Electrolyte Imbalances and Cardiac Risk: Patients with AN and BN (especially those who purge) often have severe electrolyte abnormalities (e.g., hypokalemia, hypomagnesemia, hypophosphatemia) and cardiac complications (e.g., bradycardia, hypotension, QTc prolongation). Many psychotropic medications (especially antipsychotics, some antidepressants) can also prolong the QTc interval, necessitating baseline and serial ECG monitoring. Refeeding syndrome is a critical risk during nutritional rehabilitation.
Pharmacokinetics and Pharmacodynamics: Malnutrition can alter drug absorption, distribution, metabolism, and excretion. Reduced protein binding due to hypoalbuminemia can increase free drug concentrations. Hepatic and renal impairment can alter drug clearance. These factors require careful dose adjustments and vigilant monitoring.
Drug-Drug and Drug-Nutrient Interactions: Polypharmacy is common. Be aware of potential interactions, such as those between SSRIs and other serotonergic agents (serotonin syndrome risk) or between stimulants and other sympathomimetics.
Monitoring: Regular monitoring of vital signs, weight, electrolytes, renal and hepatic function, and ECGs is crucial. Assess for medication efficacy and side effects, and adjust treatment as needed.

How It Appears on the Exam

The BCPP Board Certified Psychiatric Pharmacist exam will test your comprehensive understanding of eating disorder pharmacotherapy through various question formats. You can expect:

Clinical Vignettes: You'll be presented with patient cases detailing presenting symptoms, medical history, laboratory values (including electrolytes and ECG findings), and current medications. Questions will ask you to identify the most appropriate pharmacological intervention, recommend dosage adjustments, or identify contraindicated medications.
Drug Selection and Rationale: Questions will assess your knowledge of FDA-approved indications versus off-label uses, and the evidence supporting specific medication choices for AN, BN, and BED. You'll need to justify your selection based on efficacy, safety, and patient-specific factors.
Contraindications and Adverse Effects: Expect questions on critical contraindications (e.g., bupropion in BN/AN), major side effects (e.g., QTc prolongation, metabolic issues with olanzapine, stimulant side effects with lisdexamfetamine), and how to monitor for and manage these.
Monitoring Parameters: You must know what labs (e.g., potassium, magnesium, phosphate, LFTs, renal function) and clinical assessments (e.g., ECGs, vital signs, weight) are necessary before and during treatment.
Patient Counseling: Questions may involve scenarios requiring you to provide appropriate patient education regarding medication purpose, expected side effects, and adherence strategies.
Differentiating Between Disorders: The exam may present symptoms that could fit multiple eating disorders, requiring you to identify the correct diagnosis and subsequently the appropriate pharmacological approach.

To further prepare, consider working through BCPP Board Certified Psychiatric Pharmacist practice questions focusing on eating disorders.

Study Tips: Efficient Approaches for Mastering This Topic

Mastering eating disorder pharmaceutical interventions for the BCPP exam requires a structured and focused approach:

Know the "Big 3" Medications: Fluoxetine (BN), Lisdexamfetamine (BED), and Olanzapine (off-label AN, post-weight restoration). Understand their specific indications, dosing, and key side effects.
Memorize Contraindications: Absolutely commit to memory why bupropion is contraindicated in AN and BN. This is a common and critical test point.
Understand the "Why": Don't just memorize facts; understand the pathophysiology that dictates medication choices. Why are SSRIs generally not helpful in acute AN? Why is cardiac monitoring crucial? Connect the dots between the illness and the pharmacology.
Focus on Guidelines: Familiarize yourself with major clinical guidelines (e.g., APA, NICE) for eating disorder treatment, as these often inform exam questions.
Create Comparison Tables: Develop tables comparing AN, BN, and BED across categories like: core symptoms, primary non-pharmacological treatment, FDA-approved medications, common off-label medications, contraindicated medications, and key monitoring parameters.
Case-Based Learning: Work through as many clinical vignettes as possible. This helps you apply your knowledge to realistic patient scenarios, which is how the BCPP exam tests understanding. Look for free practice questions that include detailed clinical scenarios.
Prioritize Comorbidities: Recognize that treating co-occurring depression, anxiety, or OCD is often part of the strategy. Understand which agents are generally safe and effective in the context of an eating disorder.
Review Electrolyte and Cardiac Physiology: Brush up on the impact of malnutrition and purging on electrolytes (K, Mg, Phos) and cardiac function (QTc prolongation, bradycardia). This foundational knowledge is essential for safe medication management.

Common Mistakes: What to Watch Out For

Avoiding common pitfalls can significantly improve your score on the BCPP exam:

Misapplying Bupropion: The most frequent mistake is recommending or failing to identify bupropion as contraindicated in AN and BN due to seizure risk. Always double-check patient history for purging behaviors or low body weight.
Ignoring Non-Pharmacological Therapies: Forgetting that psychotherapy and nutritional rehabilitation are the primary treatments for all eating disorders, and pharmacotherapy is often adjunctive.
Overlooking Refeeding Syndrome: Neglecting the risk of refeeding syndrome during initial nutritional rehabilitation, especially in AN, which can lead to severe electrolyte shifts and cardiac complications.
Insufficient Monitoring: Failing to recommend appropriate monitoring (ECG, electrolytes, vital signs, weight) before and during treatment, particularly with medications that carry cardiac or metabolic risks.
Treating AN with SSRIs Pre-Weight Restoration: Recommending SSRIs as a primary treatment for AN before significant weight restoration has occurred. Their efficacy is limited in this phase, and they carry risks.
Not Considering Drug-Drug or Drug-Nutrient Interactions: Overlooking potential interactions between psychotropic medications and other drugs, or how malnutrition impacts drug pharmacokinetics.
Underestimating Comorbidity Impact: Failing to address significant comorbidities (e.g., severe depression, anxiety) that can exacerbate the eating disorder or hinder recovery.

Quick Review / Summary

Successfully navigating eating disorder pharmaceutical interventions for the BCPP exam requires a precise understanding of specific drug indications, contraindications, and monitoring. Remember these key takeaways:

Anorexia Nervosa (AN): No FDA-approved medications. Olanzapine is used off-label for weight gain/distorted thoughts, usually after initial weight restoration. SSRIs are for post-weight restoration relapse prevention or comorbid mood/anxiety.
Bulimia Nervosa (BN): Fluoxetine is the only FDA-approved medication (60 mg/day). Bupropion is absolutely contraindicated due to seizure risk.
Binge Eating Disorder (BED): Lisdexamfetamine is the only FDA-approved medication. SSRIs and topiramate are used off-label.
Avoidant/Restrictive Food Intake Disorder (ARFID): No specific pharmacotherapy; focus on behavioral interventions and treating comorbidities.
Critical Monitoring: Always assess electrolytes, ECG (QTc), vital signs, and weight, especially in patients with AN or BN, due to inherent cardiac and metabolic risks exacerbated by some psychotropics.
Bupropion Contraindication: This is a high-yield exam point for AN and BN.
Primary Treatment: Always remember that psychotherapy and nutritional rehabilitation are the cornerstones; pharmacotherapy is adjunctive.

By mastering these principles, you will be well-equipped to tackle eating disorder questions on the BCPP exam and provide expert pharmaceutical care to this vulnerable patient population.